Posted by Michael Wonder on 12 Oct 2017
First FDA approval agnostic of cancer site — when a biomarker defines the indication
11 October 2017 - In May 2017, the FDA approved pembrolizumab, a programmed death 1 inhibitor, for adult and paediatric patients with unresectable or metastatic, microsatellite-instability–high or mismatch-repair–deficient solid tumours, regardless of tumour site or histology.
